Though promising outcomes have been reported following treatment of patients with COVID-19 with immunomodulators (e.g., IL-6 inhibitors), further clinical trials are required to understand the efficacy and safety of these drugs according to disease stage and severity. The gene discussed is IL6; the disease is COVID-19.